0001209191-19-058162.txt : 20191126
0001209191-19-058162.hdr.sgml : 20191126
20191126174240
ACCESSION NUMBER: 0001209191-19-058162
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191122
FILED AS OF DATE: 20191126
DATE AS OF CHANGE: 20191126
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Huyett William
CENTRAL INDEX KEY: 0001723846
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38787
FILM NUMBER: 191252376
MAIL ADDRESS:
STREET 1: C/O CYCLERION THERAPEUTICS, INC.
STREET 2: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclerion Therapeutics, Inc.
CENTRAL INDEX KEY: 0001755237
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831895370
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-22
0
0001755237
Cyclerion Therapeutics, Inc.
CYCN
0001723846
Huyett William
C/O CYCLERION THERAPEUTICS, INC.
301 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Financial Officer
Employee Stock Option (Right to Buy)
2.01
2019-11-22
4
A
0
75000
0.00
A
2029-11-22
Common Stock
75000
75000
D
The stock option grant will vest and become exercisable upon the attainment of both performance-based and service-based hurdles, as follows: (i) 20% of the shares subject to the option, if the average closing price of the common stock reported by Nasdaq for any thirty (30) consecutive trading days equals or exceeds $10; plus an additional (ii) 40% of the shares, if the average closing price equals or exceeds $20; plus an additional (iii) 40% of the shares, if the average closing price equals or exceeds $30; in each case, subject to the continuous employment or service through the later of the date that the performance hurdles set forth above are attained (but no later than December 31, 2024) and December 31, 2021.
To the extent unvested as of December 31, 2024, all unvested shares underlying such performance-based option will be cancelled.
/s/ David Slatcher, Attorney-in-Fact
2019-11-26